Health System

A survey of new Rx, new generic, and new OTC products

The first interstate electronic exchanges of real patient information should begin shortly in Ohio, at what is expected to become a national hub that will enable information related to prescription drug monitoring to flow across state lines.

The promise of genomic discoveries is tremendous, but modern medicine is not yet ready to use the bulk of these discoveries, said Muin Khoury, MD, PhD, at the annual meeting of the American College of Clinical Pharmacology (ACCP) in Baltimore, Md.

The National Association of Chain Drug Stores Foundation received $1.76 million from 120 benefactors at its 12th annual dinner, held in New York City in November.

In this section we showcase products and product news that ran up against space limitations or fell outside the parameters of recently featured categories in the print edition. Look for more OTC Product News in upcoming issues of the Drug Topics e-newsletter.

Johnson & Johnson announced another product recall, this one involving Children's Benadryl Allergy Fastmelt Tablets, Junior Strength Motrin Caplets, and Extra Strength Rolaids softchews, the Associated Press reported.

The majority of Americans and Canadians are getting enough vitamin D and calcium to meet their needs, according to a new report from the Institute of Medicine.

The National Community Pharmacists Association installed Robert Greenwood of Iowa as its new president during the organization?s 112th Annual Convention and Trade Exposition, held in October in Philadelphia.

A team of pharmacy students from Washington State University?s College of Pharmacy won the 2010 Good Neighbor Pharmacy National Community Pharmacists Association Pruitt-Schutte Student Business Plan Competition. The announcement was made during NCPA?s 112th Annual Convention and Trade Exposition in October in Philadelphia.

The National Association of State Controlled Substances Authorities (NASCSA) has received a $200,000 grant from Purdue Pharma LP, which it will distribute to state government agencies that are able to accept private funding specifically for their state prescription-monitoring programs. NASCSA will manage the solicitation, review, and funding of the grant proposals. Selection of recipients will be based on an independent review conducted by its Special Projects Committee, which consists of association members with expertise in the fields of prescription drug abuse and diversion, and prescription drug-monitoring programs. NASCSA expects to distribute the grants by the end of 2011. The grant is part of Purdue Pharma?s efforts to support the operation, expansion, and awareness of appropriately designed state prescription drug-monitoring programs.

McNeil Consumer Healthcare, a unit of Johnson & Johnson, is voluntarily recalling nearly 128,000 bottles of Tylenol 8-hour caplets after some consumers complained of a musty or moldy odor in the products, the company announced.

In this section we showcase products and product news that ran up against space limitations or fell outside the parameters of recently featured categories in the print edition. Look for more OTC Product News in upcoming issues of the Drug Topics e-newsletter.

FDA is asking the manufacturers of gonadotropin-releasing hormone agonists to add new safety information to the Warnings and Precautions section of the drugs? labels about an increased risk of diabetes and certain cardiovascular diseases.

New safety information has been added to the label for the HIV antiviral drug saquinavir (Invirase, Genentech), describing potentially life-threatening side effects on heart function when used with ritonavir (Norvir, Abbott Laboratories), another HIV antiviral medication, FDA announced.

FDA is requiring a labeling change and Medication Guide to warn patients and healthcare providers about the possible risk of atypical thigh-bone (femoral) fracture in patients who take bisphosphonates for the prevention and treatment of osteoporosis.

For women with epilepsy, the risk of infertility increases with each additional antiepileptic drug, and more than one-third may be unable to conceive, according to research published online October 11 in Neurology and reported by HealthDay News.

Older cancer patients who receive intravenous bisphosphonate therapy may be at a modestly increased risk for atrial fibrillation (AF), supraventricular tachycardia (SVT), and stroke, according to research published online October 12 in the Journal of Clinical Oncology, HealthDay News reported.

Bromfenac ophthalmic solution (Bromday, ISTA Pharmaceuticals) 0.09% has been granted FDA approval as a once-daily prescription eyedrop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.

In patients with chronic knee pain due to osteoarthritis, 60 mg to 120 mg of duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor (SNRI), administered daily, was found to provide both significant pain control and improve physical functioning.

FDA has approved onabotulinumtoxinA (Botox, Allergan Inc.) injection to prevent headaches in adult patients with chronic migraine. To prevent chronic migraine, onabotulinumtoxinA is injected about every 12 weeks in multiple sites around the head and neck to try to dull future headache symptoms.

FDA has approved acetaminophen injection (Ofirmev, Cadence Pharmaceuticals), the first intravenous formulation of acetaminophen for the management of mild-to-moderate pain, moderate-to severe-pain with adjunctive opioid analgesics, and the reduction of fever.

FDA approved trastuzumab (Herceptin, Genentech) for use in combination with cisplatin and capecitabine or 5-fluorouracil to treat patients with human epidermal growth factor receptor 2-overexpressing metastatic gastric or gastroesophageal junction cancer who have not received prior treatment for metastatic disease.

Dabigatran etexilate (Pradaxa, Boehringer Ingelheim) has received FDA approval for the prevention of stroke and blood clots in patients with atrial fibrillation.

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., will launch its new APP Drug Hotline on Wednesday, November 10, 2010.

An updated consensus statement on the management of hypertension among African Americans places significant emphasis on a comprehensive assessment and appropriate risk stratification of individual patients with hypertension, stated a report published online October 4 in Hypertension, HealthDay News reported.

In a new randomized, placebo-controlled clinical trial published in the October 13, 2010 Journal of the American Medical Association, trial investigators demonstrated that the use of buprenorphine implants (Probuphine, Titan Pharmaceuticals) could reduce opioid use over a 24-week study period.

According to the findings of the DECISIONS survey study published in a September/October supplement of Medical Decision Making, Americans frequently find themselves faced with high blood pressure, high cholesterol, and depression medication decisions that they are ill prepared to make.

According to the findings of the DECISIONS survey study published in a September/October supplement of Medical Decision Making, Americans frequently find themselves faced with high blood pressure, high cholesterol, and depression medication decisions that they are ill prepared to make.

Lack of patient awareness coupled with ballooning numbers of diabetes cases across the United States have impelled pharmacies and organization to make diabetes care and education a priority.

In late September, presenters at the annual meeting of the Agency for Healthcare Research and Quality reported their phase 1 evaluation findings for the Pharmacy Quality Alliance medication-use demonstration project.